Axonis Therapeutics, a biotech firm specializing in neuromedicines, has raised an oversubscribed $115 million in Series A funding to support the development of its lead candidate, AXN-027. This first-in-class oral small molecule aims to enhance the CNS chloride transporter KCC2, critical for inhibitory neurotransmission, in treating epilepsy and pain. The funds will also fuel Axonis’ pipeline expansion targeting KCC2 for additional neurological disorders, including psychiatric and neurodevelopmental conditions.
The round was co-led by Cormorant Asset Management and venBio Partners, with backing from Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, and others. Axonis has also appointed new board members, Dr. Raymond J. Kelleher from Cormorant and Dr. Jonathan Leff from Sofinnova.
CEO Dr. Joanna Stanicka expressed that the funding represents a major step as Axonis approaches clinical trials. “Our goal is to deliver effective KCC2-based treatments without disabling side effects for patients with neurological disorders,” she said. Executive Chair Dr. Corey Goodman added, “We’re now positioned to move AXN-027 through proof of concept and pursue broader indications, establishing Axonis as a leader in biotech.”
